While all the aforementioned text is quite relevant from an industry point of view ie Oz biotechs are they worth investing in? the situation with OSL is that it is really no more than a binary punt until the science is proved. OSL at this stage simply boils down to will they be given an Eu approval or not.
Not all of us have the benefit of a medical or even a scientific back ground but even if you do I doubt if there is sufficient information out there to determine a chance of CE approval ie 90% chance of approval or just a 49% chance of approval. Perhaps the company knows already through its discussions in the approval process what the likely outcome is - there have been no indications either way. Is saying nothing after discussions a clue as to what might happen so let us keep our mouth shut or is it due to proper internal governance culture that obliges them to withhold any information until the full story is known?
So for me it is no more than a bet - yes there is approval or no there isn't approval. But I have to say I draw comfort from the fact that OSL have been able to attract what might be deemed industry experts out of the SRX camp and I suggest these people would not be attracted unless they felt that OSL had a good product and so were likely to succeed in a CE mark application. Thus I rate my bet at 55% to 45% in respect of being successful in their application and continue to hold.
TIS is an entirely different issue. In my opinion share holders were deceived by the management. I haven't yet been able to detect this 'quality' in the OSL team.
cheers
redgum
OSL Price at posting:
24.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)